These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19382190)

  • 1. When medical evidence alone is simply not enough.
    O'Donnell MA
    Cancer; 2009 Jun; 115(12):2602-4. PubMed ID: 19382190
    [No Abstract]   [Full Text] [Related]  

  • 2. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
    Soloway MS; Arianayagam M
    Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
    [No Abstract]   [Full Text] [Related]  

  • 3. Counter-point. Routine use of perioperative intravesical chemotherapy after TURBT: against.
    Jones JS
    Urology; 2010 Oct; 76(4):797-8. PubMed ID: 20932404
    [No Abstract]   [Full Text] [Related]  

  • 4. [Early instillation in superficial bladder carcinoma. Current status].
    Langbein S; Häcker A; Badawi JK; Michel MS; Alken P
    Urologe A; 2004 Dec; 43(12):1531-6. PubMed ID: 15592710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
    Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
    Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?
    Dobruch J; Herr H
    BJU Int; 2009 Jul; 104(2):170-4. PubMed ID: 19493266
    [No Abstract]   [Full Text] [Related]  

  • 7. Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors.
    Colombo R
    Eur Urol; 2006 Aug; 50(2):233-4. PubMed ID: 18219715
    [No Abstract]   [Full Text] [Related]  

  • 8. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
    Boccon-Gibod L
    Prog Clin Biol Res; 1992; 378():55-7. PubMed ID: 1301586
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is immediate postoperative intravesical chemotherapy beneficial in non-muscle- invasive bladder cancer?
    Ayres BE; Crew JP;
    BJU Int; 2010 Feb; 105 Suppl 2():14-7. PubMed ID: 20089093
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medical treatment of urothelial tumors of the bladder].
    Ferrière JP; Dionet C; Dauplat J; Boiteux JP; Plagne R; Giraud B
    Ann Urol (Paris); 1988; 22(4):229-34. PubMed ID: 3056230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted use of intravesical chemotherapy.
    Lerner SP; Au JL
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract]   [Full Text] [Related]  

  • 13. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of intravesical chemotherapy and possibilities for improving its efficacy.
    Sylvester RJ
    Eur Urol; 2006 Aug; 50(2):233. PubMed ID: 18219714
    [No Abstract]   [Full Text] [Related]  

  • 15. The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes).
    Lamm DL; Griffith JG
    Prog Clin Biol Res; 1992; 378():43-53. PubMed ID: 1301585
    [No Abstract]   [Full Text] [Related]  

  • 16. What matters - early start or duration of chemotherapy instillation regimens or patient characteristics?
    Kaasinen E
    Eur Urol; 2008 May; 53(5):882-5; discussion 885-6. PubMed ID: 18262339
    [No Abstract]   [Full Text] [Related]  

  • 17. The costs of intravesical chemotherapy.
    Smith PH
    Prog Clin Biol Res; 1985; 185B():39-44. PubMed ID: 4034590
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.